Labcorp Boosts FY25 Outlook

Life sciences company Labcorp (LH) has raised its full-year 2025 adjusted earnings and revenue growth guidance, reflecting strong second-quarter performance and an improved outlook. The company now projects adjusted EPS in a range of $16.05 to $16.50, up from a previous range of $15.70 to $16.40, and anticipates revenue growth of 7.5% to 8.6%, an increase from 6.7% to 8.0%. This upward revision signals positive momentum and could influence investor sentiment.

Analysis

Labcorp (LH) has issued a significant upward revision to its full-year 2025 guidance, citing strong second-quarter performance and an improved outlook. The company now forecasts adjusted earnings per share in the range of $16.05 to $16.50, an increase from the previous range of $15.70 to $16.40. Concurrently, revenue growth projections were raised to a range of 7.5% to 8.6%, up from 6.7% to 8.0%. The midpoint of the new EPS guidance ($16.275) now exceeds the current analyst consensus of $16.10, suggesting a high probability of positive revisions from the sell-side. This optimistic financial forecast is complemented by the company's commitment to shareholder returns, evidenced by the announcement of a $0.72 quarterly cash dividend. The combination of enhanced earnings expectations and a stable dividend policy signals strong operational momentum and management's confidence in sustained performance.

Key Decisions for Investors

• Given the raised guidance for both revenue and earnings, with the new EPS midpoint surpassing analyst consensus, investors may view this as a bullish catalyst underpinning existing long positions or creating a new entry point.
• Monitor for forthcoming analyst estimate revisions, as the company's updated guidance is likely to trigger upward adjustments, potentially providing further support for the stock price.
• Income-oriented investors should note the consistent $0.72 quarterly dividend, which, when coupled with the positive growth outlook, enhances the stock's total return profile.
• Consider the execution risk for the remainder of fiscal 2025, as realizing the upgraded guidance will depend on maintaining the operational momentum observed in the first half of the year.